Completed
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
NCT00509379
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Ospedale Cardinale Panico Tricase, Lecce, Italy
- Istituto Clinico Humanitas Rozzano, Milano, Italy
- Istituto per la ricerca e la cura del cancro Candiolo, Torino, Italy
- Ospedale Civico Chivasso, Torino, Italy